cor2ed
engage checkpoint medical linkedin twitter
bg

Podcast: How Can We Optimise Treatment Sequencing for mCRC Patients, 3rd Line and Beyond?

Podcast: How Can We Optimise Treatment Sequencing for mCRC Patients, 3rd Line and Beyond?

Experts discuss how physicians can use the latest data to support optimal treatment sequencing

Experts discuss how physicians can use the latest data to support optimal treatment sequencing

Prof. Jenny Seligmann, Prof. Shubham Pant

Listen to a deep-dive into optimising treatment sequencing for patients with metastatic colorectal cancer, 3rd line and beyond, from Dr Jenny Seligmann and Dr Shubham Pant.

In the podcast, the experts discuss what clinicians should consider when making treatment decisions. You'll learn about

  • the potential treatment options for patients with advanced mCRC
  • the latest available data
  • which patient considerations are important when making treatment decisions
Portrait of Jenny Seligmann
Prof. Jenny Seligmann

Medical Oncologist

University of Leeds

United Kingdom (UK)

Portrait of Shubham Pant
Prof. Shubham Pant

Medical Oncologist

MD Anderson Cancer Center

United States (US)

preview next

Treatment sequencing in advanced mCRC patients

time Podcast | open 21 min | Apr 2023

Subscribe to our podcast series on:

I agree that this educational programme:

Clinical Takeaways

  • Molecular profiling has an important role in determining treatment options and sequence

  • Physicians should consider patient characteristics, such as comorbidities, toxicities from prior treatments, and overall performance status

  • Treatment from earlier lines of therapy is critical to treatment decisions in the 3rdline and beyond

  • There are a lot of new developments in the third-line treatment space for mCRC patients

  • Patients should receive as many treatment options as possible, and this should be considered during sequencing decisions

This educational programme is supported by an Independent Medical Education Grant from Bayer

GI CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.

Other programmes of interest

preview next

Other programmes developed by Prof. Jenny Seligmann

Other programmes developed by Prof. Shubham Pant